Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1106)	11/12/2001 9:27:51 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

part 5 by: soldier30 11/12/01 08:57 pm Msg: 1296 of 1302 09:15am EST 9-Nov-01 Punk, Ziegel & Co. (Matthew Kaplan 212-891-5247) BTRN BioTransplant Reports 3Q Loss of $0.21 Per Share; Reiterate Buy Rating Abstract number 2813 Durable Progression Free Survival (PFS) Following Non-Myeloablative Bone Marrow Transplantation (BMT) for Chemorefractory Diffuse Large B Cell Lymphoma (B-LCL). Thomas R. Spitzer, Steven L. McAfee, Bimalangshu R. Dey, Robert Sackstein, Christine Colby, David H. Sachs, Megan SykesMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Chemorefractory diffuse B-LCL has a very poor prognosis with only a remote possibility of durable survival following myeloablative therapy and autologous or allogeneic BMT. In a phase I-II trial evaluating non-myeloablative bone marrow transplantation for hematologic malignancies, 20 evaluable patients had advanced B-LCL. Preparative therapy consisted of cyclophosphamide (CY 150-200 mg/kg), peri-transplant anti-T cell antibody therapy with either equine anti-thymocyte globulin (ATG) (15-30 mg/kg, days -2, -1, +1 or -1, +1, +3, +5) or monoclonal anti-CD2 antibody therapy (MEDI-507; BioTransplant, Charlestown, MA), thymic irradiation (700 cGy) in patients who had not received previous mediastinal therapy and cyclosporine beginning on day -1 with rapid taper to discontinuation by day + 35 in patients without GVHD. In pts with mixed chimerism and no evidence of GVHD, "prophylactic" donor leukocyte infusions (pDLI) were given beginning on day + 35 post-transplant. Median pt. age was 38 (20 to 62) years. The median number of prior chemoradiotherapy regimens was 3 (2 to 5) and median time from diagnosis to BMT was 12.5 (5 to 115) months. Three pts had received a prior autologous stem cell transplant (AuSCT). Ten pts were in refractory relapse, 7 pts had primary refractory disease, one pt was in a 2nd partial remission (PR) following a 2 month first complete remission (CR) and 2 were in untreated relapse following AuSCT. Ten patients received transplants from HLA matched donors, and 10 from HLA 1 to 3 antigen mismatched donors. No early (day 100) transplant related mortality occurred. One late death from aspergillosis occurred. Three of 10 HLA matched patients received prophylactic pDLI. None of the HLA mismatched patients received DLI. Acute GVHD grade II occurred in 4 of the 8 evaluable HLA matched patients following BMT. One pt developed grade IV acute GVHD and one chronic GVHD following pDLI. Five of 10 HLA mismatched patients developed grade II GVHD. Eight of 19 evaluable patients achieved a response (5 CR, 3 PR) including 3 of 10 HLA matched patients and 5 of 10 HLA mismatched patients. Five patients are alive, and progression free at 13 to 52 months post-transplant: two received an HLA matched transplant and both received pDLI, while 3 pts received an HLA mismatched transplant including one patient who had graft loss at day + 75. Two of the 5 pts have had no acute GVHD while 4 developed chronic GVHD (2 limited, 2 extensive). Durable PFS is achievable in approximately 25% of patients with chemorefractory diffuse B-LCL. These durable remissions occurred in HLA matched pts following pDLI and without DLI in HLA mismatched recipients, and notably, in some pts, without acute or chronic GVHD